Basel, Switzerland, and London, UK 21 July 2026 – Lonza, the world's leading contract development and manufacturing organization (CDMO), and Engitix, a global leader in ECM-based drug discovery and development, today announced a licensing agreement to advance the development of antibody-drug conjugates (ADCs) and deliver life-changing therapies for patients with chronic diseases.

Under the agreement, Engitix will access Lonza’s ADC technology platform through a single-target license, including the use of SYNtecan E™linker-payload and complementary GlycoConect® and HydraSpace®. These technologies will support Engitix’s goal to develop and commercialize therapies. Lonza, through one of its affiliated companies, is eligible to receive upfront, clinical, regulatory, and commercial milestone payments, plus royalties on net sales of resulting products. Lonza is responsible for manufacturing components that are related to its proprietary technologies, and Engitix is responsible for the research, development, manufacturing, and commercialization of the ADCs.

Engitix has developed a proprietary human ECM platform that allows the study of disease biology directly in human tissue.This approach focuses on targets within the ECM itself, offering a differentiated pathway compared to traditional methods that focus on cell surface targets.

The collaboration enables Engitix to leverage Lonza’s established ADC technology platform to develop differentiated therapeutic candidates designed to selectively deliver potent payloads to tumor-selective targets identified through Engitix's proprietary human ECM discovery platform.

Jan Vertommen, Vice President of Commercial Development, Advanced Synthesis, Lonza, commented: “We are pleased to collaborate with Engitix on this innovative program. By combining our ADC development and manufacturing expertise with Engitix’s unique ECM-based discovery platform, we aim to advance next-generation ADCs and unlock new possibilities in targeted therapies for patients.”

Dr. Giuseppe Mazza,CEO and Co-Founder Engitix, added: "At Engitix, we are committed to translating our unique understanding of the disease microenvironment into transformative therapies for patients with high unmet medical need. Licensing Lonza’s clinically validated conjugation and linker-payload technologies provides us with a powerful toolkit to develop next-generation ECM-targeted therapeutics with the potential for enhanced efficacy, reduced toxicity and improved therapeutic index."

The license agreement represents an important step in Engitix's strategy to build a diversified pipeline of precision therapeutics addressing fibrosis, oncology, and other diseases driven by pathological tissue remodeling.